GPX4 and lung adenocarcinoma: Moreover, ALDH1 has been proven to confer erlotinib (an epidermal growth factor receptor tyrosine-kinase inhibitor) resistance via upregulation of antioxidant enzyme, superoxidase dismutase (SOD)2, and GPX4, which downregulated the erlotinib-induced oxidative and carbonyl stress in lung adenocarcinomas [31].